Medical Doctor Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Ramana Gorrepati

Neurological Surgery Bellingham, WA Medical Doctor

NPI 1295154375 CMS profile 11261170

710 Birchwood Ave Ste 101, Bellingham, WA 98225

Open in the dashboard

General payments

$60,292

328 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Ramana Gorrepati of Bellingham, WA is reported in the CMS Open Payments database as having received $60,292 across 328 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 87th percentile of Neurological Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $20,234 101
2024 General $18,693 106
2023 General $9,021 55
2022 General $10,198 54
2021 General $2,147 12

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ramana Gorrepati
  • Neurological Surgery median
  • Middle half of Neurological Surgery
  • National median

In program year 2025, general payments to Ramana Gorrepati were reported at $20,234. Among 5,467 Neurological Surgery profiles paid that year, the median was $596 and the middle half received between $159 and $3,102.

Show as a table
Year Ramana Gorrepati Neurological Surgery median Middle half National median
2019 $0 $582 $138–$3,006 $163
2020 $0 $294 $76–$2,174 $114
2021 $2,147 $387 $105–$2,432 $132
2022 $10,198 $542 $139–$2,989 $149
2023 $9,021 $534 $145–$2,697 $160
2024 $18,693 $574 $155–$3,046 $164
2025 $20,234 $596 $159–$3,102 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Globus Medical, Inc. $19,710 76 payments
  2. Medtronic, Inc. $10,171 129 payments
  3. Nevro Corp. $10,161 20 payments
  4. SI-BONE, Inc. $6,536 44 payments
  5. Kuros Biosciences USA, Inc $4,930 8 payments
  6. Providence Medical Technology, Inc. $3,010 15 payments
  7. Centinel Spine, LLC $2,023 6 payments
  8. RTI Surgical, Inc. $1,532 4 payments
  9. Highridge Medical LLC $927 2 payments
  10. Medical Device Business Services, Inc. $321 4 payments
  11. Other $972 20 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Travel and Lodging $35,022 106 payments
  2. Food and Beverage $11,599 217 payments
  3. Compensation for serving as faculty or as a speaker for a medical education program $6,640 1 payment
  4. Consulting Fee $4,643 3 payments
  5. Education $2,388 1 payment
Products named General payments · program years 2021–2025
  1. Vyrsa V1 $6,834 6 payments
  2. MAGNETOS $4,930 8 payments
  3. SABLE $4,685 3 payments
  4. MAZOR X SYSTEM $4,134 44 payments
  5. IFUSE IMPLANT SYSTEM $2,922 10 payments
  6. EXCELSIUS GPS $2,642 11 payments
  7. UNID_PASS $2,494 27 payments
  8. Senza $2,388 1 payment
  9. ExcelsiusGPS Robotic Navigation System $2,232 7 payments
  10. CD HORIZON SPINAL SYSTEM $2,121 13 payments
  11. Other $20,512 155 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 11 drugs

Part D claims

723

Median for Neurosurgery: 83

Drug cost

$7,190

Median for Neurosurgery: $872

Branded share of claims

23.5%

Median for Neurosurgery: 16.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 134 $1,648
Pregabalin Generic 117 $1,502
Gabapentin Generic 59 $1,162
Methylprednisolone Generic 125 $969
Tizanidine Hcl Generic 101 $605
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 36 $406
Cyclobenzaprine Hcl Generic 53 $269
Methocarbamol Generic 31 $269
Dexamethasone Generic 23 $133
Tramadol Hcl Generic 29 $133

The 10 drugs with the highest cost, of 11 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,779 Part D prescribers listed as Neurosurgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 72 billing codes

Paid by Medicare

$225,443

Medicare's payments for the services billed

Medicare patients

324

Average age 74

Services billed

842

171 women, 153 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 75%
High blood pressure 73%
Ischemic heart disease 30%
Depression 27%
Diabetes 25%
Atrial fibrillation 21%
Osteoporosis 18%
Chronic kidney disease 17%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

328 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurological Surgery in Washington

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record